Astrazeneca (AZN) Other Non-Current Liabilities (2009 - 2026)

Astrazeneca (AZN) has reported Other Non-Current Liabilities for 18 consecutive years, with -$904.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 21.32% year-over-year to -$904.0 million; the TTM figure through Mar 2026 stood at -$904.0 million (up 21.32% YoY), while the FY2025 annual figure was -$918.0 million, down 199.67% from the prior year.
• Other Non-Current Liabilities came in at -$904.0 million for Q1 2026 at Astrazeneca, up from -$918.0 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $4.3 billion in Q4 2022, with the low at -$1.4 billion in Q1 2022.
• Average Other Non-Current Liabilities over 5 years is -$539.1 million, with a median of -$1.1 billion recorded in 2024.
• Across the five-year window, Other Non-Current Liabilities surged 111.81% in 2022 and sank 199.67% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $4.3 billion in 2022, then sank by 72.58% to $1.2 billion in 2023, then slipped by 21.35% to $921.0 million in 2024, then tumbled by 199.67% to -$918.0 million in 2025, then advanced by 1.53% to -$904.0 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered -$904.0 million, -$918.0 million, and -$1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.